£400k of funding approved in the fight against bowel disease
Work has now commenced on all of the 10 projects to come out of the second phase of our landmark Delphi project in collaboration with The Association of Coloproctology of Great Britain and Ireland (ACPGBI).
This brings the total amount awarded to research by BDRF through the Delphi project to £400,000.
In May 2017, these projects all passed our Association of Medical Research (AMRC) approved peer review process to become eligible for BDRF Funding. Eight projects were underway by the end of the 2017 and now the final two have been given the green light to start work.
All studies funded by the charity are automatically eligible for NIHR Clinical Research Network (CRN) support
BDRF plays a key role in seed funding innovative and cutting-edge projects, often at the very early stage of development – many of which lead on to larger scale clinical trials.
The full portfolio of projects we are working on are as follows:
|The role of risk of recurrence, bowel function and avoidance of a permanent stoma in patient preferences for treatment for rectal cancer.||Birkbeck, University of London|
|Pre-treatment molecular stratification and the histogenic origins of rectal cancer||Wellcome Trust Centre for Human Genetics & Oxford University Hospitals|
|Lipid-based biomarkers for determining radiosensitivity in rectal cancer||Department of Surgery & Cancer, Imperial College London|
|Changes in circulating biomarkers of metastatic colorectal cancer when targeting platelet tumour cell interactions with anti-platelet therapy||University of Leicester|
|Optimising management of fistulating perianal Crohn’ s||St Mark’s Hospital/London North West Healthcare NHS Trust|
|An investigation of transcutaneous vagal nerve stimulation (tVNS) on return of bowel function and inflammatory cytokine response after colorectal surgery||University of Leeds|
|Emergency Laparotomy and Frailty; A national multicentre prospective cohort study of older surgical patients (ELF study).||Royal Alexandra Hospital and University of Glasgow|
|Nrf2: a novel chemoradiotherapy resistance biomarker and interventional target for rectal cancer||University of Liverpool, Institute of Translational Medicine|
|Developing a standardised colorectal biopsy template||Countess of Chester NHS FT|
|How do surgeons decide when to avoid or defunction a rectal anastomosis? Building a theory of how surgeon and organizational factors affect decision-making.||University of East Anglia|
Chief Executive Peter Rowbottom comments; “We are really pleased to have been able to approve all 10 projects that passed through the peer review process. This will help us take one step closer to achieving our vision of one day eradicating bowel disease – but there is still a long way to go and we look forward to reporting back on the outcomes of these excellent projects and how they are helping to improve patient care”
BDRF is now working at full-tilt to raise the funds to support this crucial work – from projects to improve surgery for elderly and frail patients to the development of truly personalised cancer treatments, this research will have vital impacts on the next generation of treatments for bowel disease.
The projects encompass work to develop the most comprehensive quality of life measurement in IBD to date, and innovative studies to understand the decision-making process of both surgeons and patients when deciding whether to have a stoma after surgery.
You can be a part of changing the landscape of treatment, and bring hope to the thousands of people who rely on our work, by making a donation toward this research
Read next news article: Crohn’s research presented on the European stage